UBS Maintains Buy on Chemours, Raises Price Target to $29

Benzinga Newsdesk www.benzinga.com Positive 82.8%

Neg 0% Neu 0% Pos 82.8%

UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Buy and raises the price target from $23 to $29.

Comments

No comments yet. Be the first!